Last reviewed · How we verify

venoferrum(iron sucrose)

JW Pharmaceutical · FDA-approved active Small molecule

Iron sucrose provides bioavailable iron to replenish depleted iron stores and support hemoglobin synthesis in patients with iron deficiency anemia.

Iron sucrose provides bioavailable iron to replenish depleted iron stores and support hemoglobin synthesis in patients with iron deficiency anemia. Used for Iron deficiency anemia in patients with chronic kidney disease on hemodialysis, Iron deficiency anemia in patients with chronic kidney disease not on dialysis, Iron deficiency anemia in patients receiving erythropoiesis-stimulating agents.

At a glance

Generic namevenoferrum(iron sucrose)
SponsorJW Pharmaceutical
Drug classIron replacement agent
ModalitySmall molecule
Therapeutic areaHematology
PhaseFDA-approved

Mechanism of action

Iron sucrose is a complex of iron(III) hydroxide with sucrose that delivers iron intravenously. The iron is released and incorporated into hemoglobin and myoglobin, restoring oxygen-carrying capacity. This formulation is designed for patients who cannot tolerate or absorb oral iron, particularly those with chronic kidney disease on hemodialysis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: